07/09/2025 | Press release | Distributed by Public on 07/09/2025 14:31
Item 3.01 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On July 2, 2025, Sensei Biotherapeutics, Inc. (the "Company") received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Staff has determined that for 10 consecutive business days, from June 17, 2025 to July 1, 2025, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).
2